We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
Read MoreHide Full Article
Clovis Oncology, Inc. announced that the European Commission (“EC”) has granted approval to a label expansion of its PARP inhibitor, Rubraca (rucaparib), which will expand the drug’s eligible patient population. The drug is now approved as a maintenance treatment in recurrent ovarian cancer patients, irrespective of BRCA-mutation, who have received one prior platinum-based chemotherapy. The company is planning to launch the drug this quarter in the new indication starting with Germany.
This is the second approved indication of Rubraca in Europe. The decision was expected as the CHMP had recommended the approval last month. The FDA approved a similar label expansion of the drug in April 2018.
Investors cheered the European label expansion as shares of Clovis rose 3.9% on Jan 24. The company’s shares have rallied 46.5% in the past three months compared with the industry’s rise of 3.5%.
In Europe, Rubraca was earlier approved for BRCA-mutated, platinum-sensitive and relapsing ovarian cancer in third- or later-line setting.
The approval in second-line maintenance setting and most importantly exclusion of BRCA mutation criteria for patient selection will broaden the patient population significantly. Moreover, this brings the drug on par with other approved PARP inhibitors – AstraZeneca’s (AZN - Free Report) Lynparza and GlaxoSmithKline’s (GSK - Free Report) Zejula – for ovarian cancer in both U.S. and European markets. We remind investors that Glaxo added Zejula to its portfolio with the recently closed acquisition of TESARO Inc. for $5.1 billion.
We believe Clovis is a potential acquisition target as the merger & acquisition space heats up in the United States. The recent approval should add to its appeal as a buyout target.
However, we note that Clovis has struggled to capture market in the maintenance setting market in the United States. Rubraca sales disappointed in the third quarter after surging in the second quarter following U.S. label expansion. The effect of the company’s promotional initiatives and label expansion in Europe remains to be seen.
Moreover, the other two PARP inhibitors belong to big pharma companies with strong cash resources to promote their drugs, which can push Clovis on the back foot.
The PARP inhibitor segment is also getting competitive as several pharma/biotech companies are developing their candidates in multiple indications. In October, Pfizer’s (PFE - Free Report) Talzenna (talazoparib) received approval for treating breast cancer.
Please note that, the approval of Rubraca in maintenance setting by the EC was based on data from the confirmatory phase III study – ARIEL 3 – which showed that Rubraca led to significant improvement in progression-free survival in such patients. The company believes that Rubraca is the only PARP inhibitor to demonstrate tumor shrinkage as well as prolonged progression-free survival in this setting, which may boost its adoption.
Meanwhile, a phase III confirmatory study, ARIEL4 is evaluating Rubraca compared with chemotherapy on patients who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
Clovis Oncology, Inc. announced that the European Commission (“EC”) has granted approval to a label expansion of its PARP inhibitor, Rubraca (rucaparib), which will expand the drug’s eligible patient population. The drug is now approved as a maintenance treatment in recurrent ovarian cancer patients, irrespective of BRCA-mutation, who have received one prior platinum-based chemotherapy. The company is planning to launch the drug this quarter in the new indication starting with Germany.
This is the second approved indication of Rubraca in Europe. The decision was expected as the CHMP had recommended the approval last month. The FDA approved a similar label expansion of the drug in April 2018.
Investors cheered the European label expansion as shares of Clovis rose 3.9% on Jan 24. The company’s shares have rallied 46.5% in the past three months compared with the industry’s rise of 3.5%.
In Europe, Rubraca was earlier approved for BRCA-mutated, platinum-sensitive and relapsing ovarian cancer in third- or later-line setting.
The approval in second-line maintenance setting and most importantly exclusion of BRCA mutation criteria for patient selection will broaden the patient population significantly. Moreover, this brings the drug on par with other approved PARP inhibitors – AstraZeneca’s (AZN - Free Report) Lynparza and GlaxoSmithKline’s (GSK - Free Report) Zejula – for ovarian cancer in both U.S. and European markets. We remind investors that Glaxo added Zejula to its portfolio with the recently closed acquisition of TESARO Inc. for $5.1 billion.
We believe Clovis is a potential acquisition target as the merger & acquisition space heats up in the United States. The recent approval should add to its appeal as a buyout target.
However, we note that Clovis has struggled to capture market in the maintenance setting market in the United States. Rubraca sales disappointed in the third quarter after surging in the second quarter following U.S. label expansion. The effect of the company’s promotional initiatives and label expansion in Europe remains to be seen.
Moreover, the other two PARP inhibitors belong to big pharma companies with strong cash resources to promote their drugs, which can push Clovis on the back foot.
The PARP inhibitor segment is also getting competitive as several pharma/biotech companies are developing their candidates in multiple indications. In October, Pfizer’s (PFE - Free Report) Talzenna (talazoparib) received approval for treating breast cancer.
Please note that, the approval of Rubraca in maintenance setting by the EC was based on data from the confirmatory phase III study – ARIEL 3 – which showed that Rubraca led to significant improvement in progression-free survival in such patients. The company believes that Rubraca is the only PARP inhibitor to demonstrate tumor shrinkage as well as prolonged progression-free survival in this setting, which may boost its adoption.
Meanwhile, a phase III confirmatory study, ARIEL4 is evaluating Rubraca compared with chemotherapy on patients who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>